Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME

Gary Solomons1, Silvio E. Inzucchi2, Christoph Wanner3, David Fitchett4, Bernard Zinman5, Stefan D. Anker6, Michaela Mattheus7, Ola Vedin8, Stefan Hantel9, Søren S. Lund10

1 Boehringer Ingelheim Ltd, Bracknell, UK
2 Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA
3 Würzburg University Clinic, Würzburg, Germany
4 St. Michael’s Hospital, Division of Cardiology, University of Toronto, ON, Canada
5 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
6 Charité University, Berlin, Germany
7 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
8 Boehringer Ingelheim AB, Stockholm, Sweden
9 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
10 Boehringer Ingelheim International GmbH, Ingelheim, Germany

Discipline: 
Diabetes
Clinical taxonomy: 
Treatments for diabetes
Type 2 diabetes mellitus
Resource taxonomy: 
Posters

Information for HCPs

COVID-19 Information for Healthcare Professionals

ABCD Webinar Series

ABCD Webinars